L Number	Hits	Search Text	DB	Time stamp
1	2	5824500.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/15 12:06
7	23	kdel adj receptor	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/15 12:07
13	6	(kdel adj receptor) near3 (inhibitor or antagonist or blocker or bind)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/05/15 12:08

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653sxs

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Jun 03	New e-mail delivery for search results now available
NEWS 4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 7	Sep 03	JAPIO has been reloaded and enhanced
NEWS 8	Sep 16	Experimental properties added to the REGISTRY file
NEWS 9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 11	Oct 24	BEILSTEIN adds new search fields
NEWS 12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 13	Nov 18	DKILIT has been renamed APOLLIT
NEWS 14	Nov 25	More calculated properties added to REGISTRY
NEWS 15	Dec 04	CSA files on STN
NEWS 16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 17	Dec 17	TOXCENTER enhanced with additional content
NEWS 18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 20	Feb 13	CANCERLIT is no longer being updated
NEWS 21	Feb 24	METADEX enhancements
NEWS 22	Feb 24	PCTGEN now available on STN
NEWS 23	Feb 24	TEMA now available on STN
NEWS 24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 25	Feb 26	PCTFULL now contains images
NEWS 26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 27	Mar 20	EVENTLINE will be removed from STN
NEWS 28	Mar 24	PATDPAFULL now available on STN
NEWS 29	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 30	Apr 11	Display formats in DGENE enhanced
NEWS 31	Apr 14	MEDLINE Reload
NEWS 32	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 33	Apr 21	Indexing from 1947 to 1956 being added to records in CA/CAPLUS
NEWS 34	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 35	Apr 28	RDISCLOSURE now available on STN
NEWS 36	May 05	Pharmacokinetic information and systematic chemical names added to PHAR

NEWS EXPRESS	April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS	STN Operating Hours Plus Help Desk Availability

NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:16:58 ON 15 MAY 2003

=> File bioscience health medicine meetings pharmacology research toxicology
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	0.42

FILE 'ADISCTI' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 12:17:53 ON 15 MAY 2003

FILE 'ANABSTR' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (c) 2003 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'AQUASCI' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT 2003 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOCOMMERCE' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOSIS' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHABS' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHDS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHNO' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 12:17:53 ON 15 MAY 2003

FILE 'CAPLUS' ENTERED AT 12:17:53 ON 15 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (c) 2003 DECHEMA eV

FILE 'CEN' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 12:17:53 ON 15 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DDFB' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DDFU' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DGENE' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGB' ACCESS NOT AUTHORIZED

FILE 'DRUGLAUNCH' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGMONOG2' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGNL' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGU' ACCESS NOT AUTHORIZED

FILE 'DRUGUPDATES' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'EMBASE' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 12:17:53 ON 15 MAY 2003

FILE 'FOMAD' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 International Food Information Service

FILE 'GENBANK' ENTERED AT 12:17:53 ON 15 MAY 2003

FILE 'HEALSAFE' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 IFI CLAIMS(R) Patent Services (IFI)

FILE 'JICST-EPLUS' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 Japan Science and Technology Corporation (JST)

FILE 'KOSMET' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (c) 2003 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 12:17:53 ON 15 MAY 2003

FILE 'NIOSHTIC' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 12:17:53 ON 15 MAY 2003
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2003)

FILE 'NUTRACEUT' ENTERED AT 12:17:53 ON 15 MAY 2003
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 12:17:53 ON 15 MAY 2003
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2003 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 WIPO

FILE 'PHAR' ENTERED AT 12:17:53 ON 15 MAY 2003

COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 12:17:53 ON 15 MAY 2003
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 Gale Group. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT 2003 THOMSON ISI

FILE 'SYNTHLINE' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 Prous Science

FILE 'TOXCENTER' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 ACS

FILE 'USPATFULL' ENTERED AT 12:17:53 ON 15 MAY 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 12:17:53 ON 15 MAY 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'VETU' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPINDEX' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'CBNB' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (c) 2003 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CHEMLIST' ENTERED AT 12:17:53 ON 15 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'CSNB' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (c) 2003 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ENERGY' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (c) 2003 USDOE for the IEA-Energy Technology Data Exchange (ETDE)

FILE 'HSDB' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 NATIONAL LIBRARY OF MEDICINE

FILE 'INIS' ACCESS NOT AUTHORIZED

FILE 'IPA' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 American Society of Hospital Pharmacists (ASHP)

FILE 'MSDS-CCOHS' ENTERED AT 12:17:53 ON 15 MAY 2003
Copyright Notice: Permission to copy is not required for this file

FILE 'MSDS-OHS' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 MDL INFORMATION SYSTEMS (MDL)

FILE 'NAPRALERT' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 Board of Trustees of the University of Illinois,
University of Illinois at Chicago.

FILE 'NLDB' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 Gale Group. All rights reserved.

FILE 'POLLUAB' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'RTECS' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 U.S. Secretary of Commerce on Behalf of the U.S. Government (DOC)

FILE '1MOBILITY' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 Society of Automotive Engineers, Inc.

FILE 'COMPENDEX' ENTERED AT 12:17:53 ON 15 MAY 2003
Compendex Compilation and Indexing (C) 2003
Elsevier Engineering Information Inc (EEI). All rights reserved.
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'COMPUAB' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'CONF' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (c) 2003 FIZ Karlsruhe

FILE 'ELCOM' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'IMSDRUGCONF' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd.

FILE 'PAPERCHEM2' ENTERED AT 12:17:53 ON 15 MAY 2003
Paperchem2 compilation and indexing (C) 2003
Elsevier Engineering Information Inc. All rights reserved.

FILE 'SOLIDSTATE' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'BABS' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (c) 2003 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein Chemiedaten & Software GmbH and MDL Information Systems GmbH

FILE 'DIOGENES' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 FOI Services, Inc. (FOI)

FILE 'INVESTEXT' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 Thomson Financial Services, Inc. (TFS)

FILE 'USAN' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 U.S. Pharmacopeial Convention, Inc. (USPC)

```
FILE 'DKF' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 Dokumentation Kraftfahrwesen e.V., Germany

FILE 'FORIS' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 Informationszentrum Sozialwissenschaften, Bonn (IZS)

FILE 'FORKAT' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 Bundesministerium fuer Bildung,
Wissenschaft, Forschung und Technologie (bmb+f)

FILE 'RUSSCI' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 Andrigal Ltd.

FILE 'SOLIS' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 Informationszentrum Sozialwissenschaften, Bonn (IZS)

FILE 'UFORDAT' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 Umweltbundesamt, D-14191 Berlin (UBA)

FILE 'AQUIRE' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 US Environmental Protection Agency (EPA)

FILE 'ULIDAT' ENTERED AT 12:17:53 ON 15 MAY 2003
COPYRIGHT (C) 2003 Umweltbundesamt, D-14191 Berlin (UBA)

=> s (kdel (w) receptor)
  23 FILES SEARCHED...
  47 FILES SEARCHED...
  82 FILES SEARCHED...
L1          860 (KDEL (W) RECEPTOR)

=> s l1 (3A) (inhibitor or antagonist or blocker or bind)
  18 FILES SEARCHED...
  35 FILES SEARCHED...
  57 FILES SEARCHED...
  87 FILES SEARCHED...
L2           72 L1 (3A) (INHIBITOR OR ANTAGONIST OR BLOCKER OR BIND)

=> s l2 and (polynucleotide or gene or clone or dna or (nucleic acid) or nucleotide)
   9 FILES SEARCHED...
  13 FILES SEARCHED...
  14 FILES SEARCHED...
  23 FILES SEARCHED...
  30 FILES SEARCHED...
  36 FILES SEARCHED...
  41 FILES SEARCHED...
  48 FILES SEARCHED...
  57 FILES SEARCHED...
  58 FILES SEARCHED...
  62 FILES SEARCHED...
  80 FILES SEARCHED...
L3           50 L2 AND (POLYNUCLEOTIDE OR GENE OR CLONE OR DNA OR (NUCLEIC
                ACID) OR NUCLEOTIDE)

=> duplicate
ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove
ENTER L# LIST OR (END):l3
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGLAUNCH, DRUGMONOG2, DRUGUPDATES, FEDRIP, FOREGE, GENBANK, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, SYNTHLINE, CHEMLIST, HSDB,
MSDS-CCOHS, MSDS-OHS, RTECS, CONF, IMSDRUGCONF, DIOGENES, INVESTEXT, USAN,
FORIS, FORKAT, UFORDAT, AQUIRE'.
```

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
DUPLICATE PREFERENCE IS 'BIOSIS, BIOTECHABS, CAPLUS, DGENE, IFIPAT, USPATFULL, WPINDEX'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L3
L4 46 DUPLICATE REMOVE L3 (4 DUPLICATES REMOVED)

=> s l4 NOT patent
21 FILES SEARCHED...
45 FILES SEARCHED...
72 FILES SEARCHED...
L5 9 L4 NOT PATENT

=> d l5 1-9 bib ab

L5 ANSWER 1 OF 9 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AN 2001:185685 BIOSIS
DN PREV200100185685
TI Human KDEL receptor.
AU Bandman, Olg; Hillman, Jennifer L.; Goli, Surya K.
ASSIGNEE: Incyte Pharmaceuticals, Inc.
PI US 6103874 August 15, 2000
SO Official Gazette of the United States Patent and Trademark Office Patents, (Aug. 15, 2000) Vol. 1237, No. 3, pp. No Pagination. e-file.
ISSN: 0098-1133.
DT Patent
LA English
AB The present invention provides a novel human KDEL receptor (NHKR) and **polynucleotides** which identify and encode NHKR. The invention also provides genetically engineered expression vectors and host cells comprising the **nucleic acid** sequences encoding NHKR and a method for producing NHKR. The invention also provides for agonists, antibodies, or antagonists specifically binding NHKR, and their use, in the prevention and treatment of diseases associated with expression of NHKR. Additionally, the invention provides for the use of antisense molecules to **polynucleotides** encoding NHKR for the treatment of diseases associated with the expression of NHKR. The invention also provides diagnostic assays which utilize the **polynucleotide**, or fragments or the complement thereof, and antibodies specifically binding NHKR.

L5 ANSWER 2 OF 9 BIOTECHABS COPYRIGHT 2003 THOMSON DERWENT AND ISI
AN 2002-12171 BIOTECHABS
TI **Gene**-delivery compound for targeted **gene** delivery, comprises single-chain binding polypeptide having effector segment with cysteinyl residue and **nucleic acid** -binding/lipid-associating moiety coupled to polypeptide by residue; single chain antibody-mediated **gene** transfer and expression in host cell for **gene** therapy
AU HUSTON J S; WILS P; QUAN Z; LAURENT O; MARASCO W A; SCHERMAN D
PA HUSTON J S; WILS P; QUAN Z; LAURENT O; MARASCO W A; SCHERMAN D
PI WO 2002000914 3 Jan 2002
AI WO 2000-US20182 23 Jun 2000
PRAI US 2000-213653 23 Jun 2000
DT Patent
LA English
OS WPI: 2002-268789 [31]
AB DERWENT ABSTRACT:
NOVELTY - A **gene**-delivery compound (I) comprising a single-chain binding polypeptide (SCBP) having at least one effector segment having a cysteinyl residue and a **nucleic acid** -binding moiety (NABM) or a lipid-associating moiety (LAM) coupled to

SCBP by the residue, is new.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a composition (II) comprising (I) and a **nucleic acid** associated reversibly with NABM, or a liposome in association with LAM.

BIOTECHNOLOGY - Preferred Compound: In (I), the binding region of SCBP is effective in binding two or more surface markers of a mammalian cell, and comprises a single-chain Fv protein, where the marker is a tumor antigen from erbB-2, erbB-3, erbB-4, p53, p21 ras, transferrin receptor, Lewis Y antigen, carcinoembryonic antigen, epidermal growth factor, MUC1, and any other tumor-associated or tumor-specific antigen. NABM is preferably from salmon protamine, subfragments of salmon protamine, human histone H1, subfragments of human histone H1, human protamine, subfragments of human protamine, HMG, polylysine or any other **DNA** binding polypeptide; and LAM is from linear, branched, cyclic, and polycyclic compounds capable of insertion into and retention of lipid-containing compositions, where LAM contains polyethylene glycol (PEG) and preferably is maleimide-PEG-(C18)2, in which the PEG portion has about 10-100 oxyethyl units. (I) further comprises an additional effector segment that binds reversibly with **nucleic acids**, or that facilitates endosomal escape or avoidance, non-endosomal transport in a cell, or entry into the nucleus of a targeted cell, where the effector segment is a human histone H1 peptide sequence which comprises the carboxyl-terminal sequence that **binds** to the **KDEL receptor** in the Golgi, SEKDEL, or comprises SV40 large T antigen nuclear localization sequence, TPPKKKRKV. (I) further comprises a spacer sequence which is located between the effector segment containing the cysteinyl residue and an additional effector segment, where the spacer sequence comprises one or two segments of SSSSG or GGGGS. In (I), the cysteinyl residue is coupled to NABM by a heterobifunctional crosslinking agent which is preferably from succinimidyl trans-4(maleimidylmethyl)-cyclohexane-1-carboxylate (SMCC) and sulfoSMCC. Preferred Composition: In (II), the **nucleic acid** comprises **DNA** encoding a therapeutic **gene** which is a lymphokine, a tumor necrosis factor, or an intrabody; or is from tumor suppressor **genes**, p53, proapoptotic **genes**, suicide **genes**, prodrug converting **genes**, HSV-TK and anti-angiogenic **genes**. In (II) comprising a liposome, SCBP is located on a surface of the liposome which is a stealth liposome.

ACTIVITY - None given in the source material.

MECHANISM OF ACTION - **Gene** therapy. No supporting data is given.

USE - (I) is useful for targeted **gene** delivery for treating diseases by **gene** therapy.

ADMINISTRATION - (I) is administered preferably through intravascular and subcutaneous injection, topical application and oral ingestion. No specific dosage detail is given.

ADVANTAGE - (I) is utilized to provide targeted non-viral delivery of **gene** to target cells, and (I) having the ability to bind to multiple, different surface markers on a target cell, can be utilized for multi-site targeting.

EXAMPLE - The single-chain binding polypeptides based on two anti-c-erbB-2 single-chain sFv was utilized, where the analog of C6.5 sFv Schier et al., Immunotechnology, Vol, 1, 73-81 (1995), preferably C6ML3-9 sFv Schier et al., J. Mol. Biol., Vol. 263, 551-567 (1996), was prepared by modifying the complementarity determining regions (CDRs) of C6.5. A heterobifunctional linker, sulfo-succinimidyl trans-4(maleimidylmethyl)-cyclohexane-1-carboxylate (sulfo-SMCC) was used to couple salmon protamine via its alpha amino terminal group to the C-terminal sulfhydryl of C6ML3-9 sFv, and finally the desired **DNA** e.g. therapeutic **gene** was added. **Gene** delivery experiments were carried out with the anti-erbB-2 sFv'-(salmon protamine)-**DNA** complex (C6.5 sFv'-SP-**DNA** or C6ML3-9 sFv'-SP-**DNA**). The

results showed that the conjugates were able to transfect c-erbB-2 positive cells. (96 pages)

L5 ANSWER 3 OF 9 BIOTECHABS COPYRIGHT 2003 THOMSON DERWENT AND ISI
AN 2000-06139 BIOTECHABS
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion or proteins which are normally retained within the cell;
herpes simplex virus-based vector e.g. plasmid pHSV1, retro virus vector and Moloney retro virus vector-mediated expression in transgenic animal for infectious disease and cancer therapy
AU Rothman J E; Mayhew M; Hoe M H AP
PA Sloan-Kettering-Inst.Cancer-Res.
LO New York, NY, USA.
PI WO 2000006729 10 Feb 2000
AI WO 1999-US17147 28 Jul 1999
PRAI US 1998-124671 29 Jul 1998
DT Patent
LA English
OS WPI: 2000-195296 [17]
AB An oligomeric **KDEL receptor inhibitor** protein which promotes secretion of proteins normally retained within the cell is new. The inhibitor protein contains several subunits where each subunit contains an oligomerization domain and has at its carboxy terminus a region which **binds** to a **KDEL receptor**. Also claimed are: a **nucleic acid** encoding the **KDEL receptor-inhibitor**; a non-human transgenic animal carrying a transgenic **KDEL receptor inhibitor** protein linked to a promoter sequence; increasing the secretion of a protein by a cell; promoting the release of heat shock protein/antigenic peptide complex from a cell; and inducing or increasing an immune response to a target antigen. Vectors include herpes simplex virus based vectors e.g. plasmid pHSV1, retro virus vectors e.g. MFG and in particular Moloney retro virus vectors such as LN, LNSX, LNCX and LXSN. The KDEL receptors can be used to promote secretion of proteins such as heat shock proteins thereby making them more accessible to the immune system and improving the immune response. The methods may be used for treating infectious disease or cancer. Secretion of genetically engineered proteins may also be achieved. (87pp)

L5 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2003 ACS
AN 2000:98760 CAPLUS
DN 132:133894
TI Inhibition of KDEL receptor-mediated return of heat shock protein complexes to the endoplasmic reticulum and their adjuvant use
IN Rothman, James E.; Mayhew, Mark; Hoe, Mee H. AP
PA Sloan-Kettering Institute for Cancer Research, USA
SO PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000006729	A1	20000210	WO 1999-US17147	19990728

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6160088	A	20001212	US 1998-124671	19980729
CA 2337692	AA	20000210	CA 1999-2337692	19990728
AU 9953245	A1	20000221	AU 1999-53245	19990728
EP 1100906	A1	20010523	EP 1999-938851	19990728

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

PRAI US 1998-124671	A	19980729	
WO 1999-US17147	W	19990728	

AB **Inhibitors** of the **KDEL receptor** that can be used to block the transfer of heat shock proteins to the endoplasmic reticulum and allow them to act as adjuvants are described. Certain proteins are functionally retained in the cellular endoplasmic reticulum via an interaction between a KDEL sequence and its receptor. According to the invention, blocking this interaction with a **KDEL receptor inhibitor** promotes the secretion of such proteins. In specific embodiments of the invention, **KDEL receptor inhibitors** may be used to promote the secretion of heat shock proteins, thereby rendering the secreted heat shock proteins more accessible to the immune system and improving the immune response to heat shock protein-assocd. antigens. The inhibitors are artificial peptides that oligomerize and present large no. of KDEL peptides to the receptors and sat. them. An example of one of these peptides uses the signal peptide of the BiP protein, an oligomerization domain of a cartilage oligomeric matrix protein, a linker peptide from a camel Ig and a KDEL peptide is described.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2003 ACS
AN 1998:359390 CAPLUS
DN 129:147072
TI Hsp47 **binds** to the **KDEL receptor** and cell surface expression is modulated by cytoplasmic and endosomal pH
AU Sauk, John J.; Norris, Kathleen; Hebert, Carla; Ordonez, Jose; Reynolds, Mark
CS Department of Pathology, Dental School and UMAB Greenbaum Cancer Center, University of Maryland at Baltimore, Baltimore, MD, 21201, USA
SO Connective Tissue Research (1998), 37(1-2), 105-119
CODEN: CVTRBC; ISSN: 0300-8207
PB Gordon & Breach Science Publishers
DT Journal
LA English

Not inhibit
Not NT

AB Hsp47 is a novel glycoprotein that binds specifically to procollagen and is retained in the ER by its COOH-terminus RDEL peptide sequence (Satoh, M. et al. Jol. Cell Biol. 1996; 133: 469-83). In this paper, we report that erd2P, the KDEL receptor, is distributed, coppts. with, and binds to Hsp47. Also, under stress conditions and lowering of pHi, the cytoplasmic epitope of erd2P is not recognized by erd2P antibodies unless the cells are pretreated with NEM. Coincident with the masking of the cytoplasmic epitope of erd2P, following lowering of pHi, Hsp47 is not retained but eludes its retention receptor to be expressed on the cell surface. Alkalization of the endosomal compartments by treatment with NH4Cl or chloroquine also results in the loss of Hsp47 to the cell surface, presumably by inhibiting the retrieval of trans-Golgi network proteins from the cell surface. The expression of Hsp47 on the cell surface under conditions of stress and alteration of pHi and pHe posture Hsp47 as a serpin family protein that may modulate cell migration during development and invasion and metastasis in cancer.

RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2003 ACS
AN 1996:428695 CAPLUS
DN 125:79781
TI Purification and Characterization of the Human KDEL Receptor
AU Scheel, Andreas A.; Pelham, Hugh R. B.
CS MRC Laboratory of Molecular Biology, Cambridge, CB2 2QH, UK
SO Biochemistry (1996), 35(31), 10203-10209
CODEN: BICHAW; ISSN: 0006-2960
PB American Chemical Society
DT Journal
LA English
AB Retention of sol. endoplasmic reticulum (ER) proteins is ensured by their continuous retrieval from subsequent compartments in the secretory pathway. Sol. ER proteins which escape to the Golgi app. **bind** to the **KDEL receptor**, a seven-transmembrane receptor, and are then returned to the endoplasmic reticulum. We have overexpressed the human KDEL receptor in insect cells using the baculovirus system. Infected cells accumulate large amts. of functional receptor as judged by a ligand binding assay. A hexahistidine-tagged version of the receptor could be purified in a single step to near-homogeneity with high yield. After reconstitution of purified KDEL receptor into liposomes, a similar affinity and pH dependence for the binding of KDEL peptides was obsd. compared to the receptor in its natural environment, indicating that purified KDEL receptor is sufficient for specific and pH-sensitive binding of KDEL ligands. Detn. of the receptor affinity in different lipid environments revealed that the receptor affinity is only slightly influenced by its lipid environment, suggesting that regulation of the receptor affinity by its surrounding lipids does not play a crucial role for the sorting of KDEL proteins.

L5 ANSWER 7 OF 9 IFIPAT COPYRIGHT 2003 IFI
AN 10189286 IFIPAT;IFIUDB;IFICDB
TI BIOENGINEERED VEHICLES FOR TARGETED **NUCLEIC ACID** DELIVERY
INF Huston; James S., Chestnut Hill, MA, US
Laurent; Oliver, Berkley, CA, US
Marasco; Wayne A., Oakland, CA, US
Scherman; Daniel, Paris, FR
Wils; Pierre, Paris, FR
Zhu; Quan, Needham, MA, US
IN Huston James S; Laurent Oliver; Marasco Wayne A; Scherman Daniel (FR); Wils Pierre (FR); Zhu Quan
PAF Unassigned
PA Unassigned Or Assigned To Individual (68000)
AG Patrick J. Kelly Synnestvedt & Lechner LLP, 2600 Aramark Tower, 1101 Market Street Philadelphia, PA, 19107, US
PI US 2002132990 A1 20020919
AI US 2001-888721 20010625
PRAI US 2000-213653P 20000623 (Provisional)
FI US 2002132990 20020919
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 52
GI 26 Figure(s).
FIG. 1 is a diagrammatic representation of a single-chain binding polypeptide of the present invention. Part (a) is the extended polypeptide format, and Part (b) is the folded protein format;
FIG. 2 is a diagrammatic representation of a single-chain binding polypeptide of the present invention illustrating the location of the

complementarity determining regions, the polypeptide spacer regions, and the effector regions;
FIG. 3 is the amino acid sequence for C6.5 sFv;
FIG. 4 is the **nucleotide** sequence for C6.5 sFv;
FIG. 5 is the amino acid sequence for C6ML3-9 sFv';
FIG. 6 is the **nucleotide** sequence for C6ML3-9 sFv';
FIG. 7 is the amino acid sequence for C6ML3-9 sFv'-L1-KDEL;
FIG. 8 is the **nucleotide** sequence for C6ML3-9 sFv'-L1-KDEL;
FIG. 9 is the amino acid sequence for C6ML3-9 sFv'-L2-KDEL;
FIG. 10 is the **nucleotide** sequence for C6ML3-9 sFv'-L2-KDEL;
FIG. 11 is the amino acid sequence for C6ML3-9 sFv'-L2-H14;
FIG. 12 is the **nucleotide** sequence for C6ML3-9 sFv'-L2-H14;
FIG. 13 is the amino acid sequence for C6ML3-9 sFv'-L2-nls; nls is the SV40 large T antigen nuclear localization signal.
FIG. 14 is the **nucleotide** sequence for C6ML3-9 sFv'-L2-nls;
FIG. 15 shows that C6ML3-9 sFv' and its conjugate to salmon protamine (SP) bind specifically to erbB-2 positive ovarian cancer cells;
FIG. 16 shows a FACS analysis of the erbB-2 binding activities of bacterially expressed C6ML3-9 sFv' and its derivatives;
FIG. 17 is a gel shift analysis of C6.5 sFv'-SP-**DNA** and C6ML3-9 sFv'-SP-**DNA** complexes;
FIG. 18 shows a kinetic study of C6.5 sFv'-SP-**DNA** and C6ML3-9-SPDNA complex formation;
FIG. 19 shows that a C6ML3-9 sFv-SP conjugate protein mediates specific luciferase **gene** delivery to erbB-2 positive cancer cells;
FIG. 20 illustrates chloroquine-dependence of C6ML3-9 sFv'-SPmediated **gene** delivery;
FIG. 21 illustrates fluorescent microscopy of C6.5 sFv'-SP and C6ML3-9 sFv'-SP-mediated **gene** transfer of pGeneGrip Rhodamine/ GFP plasmids with SK-OV-3 and MCF-7;
FIG. 22 illustrates the effect of chloroquine on 3T3-HER2 transfection mediated by C6ML3-9 sFv'-salmon protamine;
FIG. 23 illustrates the effect of chloroquine on 3T3-HER2 transfection mediated by C6ML3-9 sFv'-P1;
FIG. 24 illustrates the effect of chloroquine on 3T3-HER2 transfection mediated by C6ML3-9 sFv'-H1;
FIG. 25 illustrates the effect of C6ML3-9 sFv'-H1-pBks on 3T3HER2 transfection mediated by C6ML3-9 sFv'-H1; and
FIG. 26 illustrates the effect of the **DNA** to C6ML3-9 sFv'-H1 ratio on 3T3-HER2 transfection efficiency.

AB There is disclosed a **gene**-delivery compound comprising: (A) a single-chain binding polypeptide having at least one effector segment which includes at least one cysteinyl residue; and (B) a **nucleic acid**-binding moiety which is coupled to the polypeptide via the cysteinyl residue. There is disclosed also a **gene**-delivery compound comprising: (A) a single-chain, binding polypeptide having at least one effector segment which includes at least one cysteinyl residue; (B) a lipidassociating moiety which is coupled to the polypeptide via the cysteinyl residue. Additionally disclosed are compositions comprising the above-mentioned compounds and a **nucleic acid**.

L5 ANSWER 8 OF 9 USPATFULL
AN 2000:168135 USPATFULL
TI **KDEL receptor inhibitors**
IN Rothman, James E., New York, NY, United States AP
Mayhew, Mark, Tarrytown, NY, United States
Hoe, Mee H., Irvington, NY, United States
PA Sloan-Kettering Institute For Cancer, New York, NY, United States (U.S. corporation)
PI US 6160088 20001212
AI US 1998-124671 19980729 (9) parent
DT Utility

FS Granted
EXNAM Primary Examiner: Achutamurthy, Ponnathapu; Assistant Examiner: Tung, Peter P.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 10 Drawing Figure(s); 30 Drawing Page(s)
LN.CNT 1537
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to **inhibitors** of the **KDEL receptor** and therapeutic uses therefor. Certain proteins are functionally retained in the cellular endoplasmic reticulum via an interaction between a KDEL sequence and its receptor. According to the invention, blocking this interaction with a **KDEL receptor inhibitor** promotes the secretion of such proteins. In specific embodiments of the invention, **KDEL receptor inhibitors** may be used to promote the secretion of heat shock proteins, thereby rendering the secreted heat shock proteins more accessible to the immune system and improving the immune response to heat shock protein-associated antigens.

L5 ANSWER 9 OF 9 WPINDEX (C) 2003 THOMSON DERWENT
AN 2002-268789 [31] WPINDEX
DNC C2002-079652
TI **Gene**-delivery compound for targeted **gene** delivery, comprises single-chain binding polypeptide having effector segment with cysteinyl residue and **nucleic acid**-binding/lipid-associating moiety coupled to polypeptide by residue.
DC A96 B04 D16
IN HUSTON, J S; LAURENT, O; MARASCO, W A; SCHERMAN, D; WILS, P; ZHU, Q; QUAN, Z
PA (HUST-I) HUSTON J S; (LAUR-I) LAURENT O; (MARA-I) MARASCO W A; (SCHE-I) SCHERMAN D; (WILS-I) WILS P; (ZHUQ-I) ZHU Q; (QUAN-I) QUAN Z
CYC 96
PI WO 2002000914 A2 20020103 (200231)* EN 96p
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
AU 2001070142 A 20020108 (200235)
US 2002132990 A1 20020919 (200264)
ADT WO 2002000914 A2 WO 2001-US20182 20010625; AU 2001070142 A AU 2001-70142 20010625; US 2002132990 A1 Provisional US 2000-213653P 20000623, US 2001-888721 20010625
FDT AU 2001070142 A Based on WO 200200914
PRAI US 2000-213653P 20000623; US 2001-888721 20010625
AB WO 200200914 A UPAB: 20021031
NOVELTY - A **gene**-delivery compound (I) comprising a single-chain binding polypeptide (SCBP) having at least one effector segment having a cysteinyl residue and a **nucleic acid**-binding moiety (NABM) or a lipid-associating moiety (LAM) coupled to SCBP by the residue, is new.
DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a composition (II) comprising (I) and a **nucleic acid** associated reversibly with NABM, or a liposome in association with LAM.
ACTIVITY - None given in the source material.
MECHANISM OF ACTION - **Gene** therapy. No supporting data is given.
USE - (I) is useful for targeted **gene** delivery for treating diseases by **gene** therapy.
ADVANTAGE - (I) is utilized to provide targeted non-viral delivery of

gene to target cells, and (I) having the ability to bind to multiple, different surface markers on a target cell, can be utilized for multi-site targeting.
Dwg.0/26

=>
<------User Break------>

=> d 14 1-46 bib

L4 ANSWER 1 OF 46 IFIPAT COPYRIGHT 2003 IFI DUPLICATE 1
AN 10189286 IFIPAT;IFIUDB;IFICDB
TI BIOENGINEERED VEHICLES FOR TARGETED **NUCLEIC ACID** DELIVERY
INF Huston; James S., Chestnut Hill, MA, US
Laurent; Oliver, Berkley, CA, US
Marasco; Wayne A., Oakland, CA, US
Scherman; Daniel, Paris, FR
Wils; Pierre, Paris, FR
Zhu; Quan, Needham, MA, US
IN Huston James S; Laurent Oliver; Marasco Wayne A; Scherman Daniel (FR); Wils Pierre (FR); Zhu Quan
PAF Unassigned
PA Unassigned Or Assigned To Individual (68000)
AG Patrick J. Kelly Synnestvedt & Lechner LLP, 2600 Aramark Tower, 1101 Market Street Philadelphia, PA, 19107, US
PI US 2002132990 A1 20020919
AI US 2001-888721 20010625
PRAI US 2000-213653P 20000623 (Provisional)
FI US 2002132990 20020919
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 52
GI 26 Figure(s).
FIG. 1 is a diagrammatic representation of a single-chain binding polypeptide of the present invention. Part (a) is the extended polypeptide format, and Part (b) is the folded protein format;
FIG. 2 is a diagrammatic representation of a single-chain binding polypeptide of the present invention illustrating the location of the complementarity determining regions, the polypeptide spacer regions, and the effector regions;
FIG. 3 is the amino acid sequence for C6.5 sFv;
FIG. 4 is the **nucleotide** sequence for C6.5 sFv;
FIG. 5 is the amino acid sequence for C6ML3-9 sFv';
FIG. 6 is the **nucleotide** sequence for C6ML3-9 sFv';
FIG. 7 is the amino acid sequence for C6ML3-9 sFv'-L1-KDEL;
FIG. 8 is the **nucleotide** sequence for C6ML3-9 sFv'-L1-KDEL;
FIG. 9 is the amino acid sequence for C6ML3-9 sFv'-L2-KDEL;
FIG. 10 is the **nucleotide** sequence for C6ML3-9 sFv'-L2-KDEL;
FIG. 11 is the amino acid sequence for C6ML3-9 sFv'-L2-H14;
FIG. 12 is the **nucleotide** sequence for C6ML3-9 sFv'-L2-H14;
FIG. 13 is the amino acid sequence for C6ML3-9 sFv'-L2-nls; nls is the SV40 large T antigen nuclear localization signal.
FIG. 14 is the **nucleotide** sequence for C6ML3-9 sFv'-L2-nls;
FIG. 15 shows that C6ML3-9 sFv' and its conjugate to salmon protamine (SP) bind specifically to erbB-2 positive ovarian cancer cells;
FIG. 16 shows a FACS analysis of the erbB-2 binding activities of bacterially expressed C6ML3-9 sFv' and its derivatives;
FIG. 17 is a gel shift analysis of C6.5 sFv'-SP-**DNA** and C6ML3-9 sFv'-SP-**DNA** complexes;
FIG. 18 shows a kinetic study of C6.5 sFv'-SP-**DNA** and C6ML3-9-SPDNA complex formation;
FIG. 19 shows that a C6ML3-9 sFv-SP conjugate protein mediates specific luciferase **gene** delivery to erbB-2 positive cancer cells;

FIG. 20 illustrates chloroquine-dependence of C6ML3-9 sFv'-SPmediated **gene** delivery;
FIG. 21 illustrates fluorescent microscopy of C6.5 sFv'-SP and C6ML3-9 sFv'-SP-mediated **gene** transfer of pGeneGrip Rhodamine/ GFP plasmids with SK-OV-3 and MCF-7;
FIG. 22 illustrates the effect of chloroquine on 3T3-HER2 transfection mediated by C6ML3-9 sFv'-salmon protamine;
FIG. 23 illustrates the effect of chloroquine on 3T3-HER2 transfection mediated by C6ML3-9 sFv'-P1;
FIG. 24 illustrates the effect of chloroquine on 3T3-HER2 transfection mediated by C6ML3-9 sFv'-H1;
FIG. 25 illustrates the effect of C6ML3-9 sFv'-H1-pBks on 3T3HER2 transfection mediated by C6ML3-9 sFv'-H1; and
FIG. 26 illustrates the effect of the **DNA** to C6ML3-9 sFv'-H1 ratio on 3T3-HER2 transfection efficiency.

L4 ANSWER 2 OF 46 BIOTECHABS COPYRIGHT 2003 THOMSON DERWENT AND ISI
AN 2002-12171 BIOTECHABS
TI **Gene**-delivery compound for targeted **gene** delivery, comprises single-chain binding polypeptide having effector segment with cysteinyl residue and **nucleic acid** -binding/lipid-associating moiety coupled to polypeptide by residue; single chain antibody-mediated **gene** transfer and expression in host cell for **gene** therapy
AU HUSTON J S; WILS P; QUAN Z; LAURENT O; MARASCO W A; SCHERMAN D
PA HUSTON J S; WILS P; QUAN Z; LAURENT O; MARASCO W A; SCHERMAN D
PI WO 2002000914 3 Jan 2002
AI WO 2000-US20182 23 Jun 2000
PRAI US 2000-213653 23 Jun 2000
DT Patent
LA English
OS WPI: 2002-268789 [31]

L4 ANSWER 3 OF 46 WPINDEX (C) 2003 THOMSON DERWENT
AN 2002-268789 [31] WPINDEX
DNC C2002-079652
TI **Gene**-delivery compound for targeted **gene** delivery, comprises single-chain binding polypeptide having effector segment with cysteinyl residue and **nucleic acid**-binding/lipid-associating moiety coupled to polypeptide by residue.
DC A96 B04 D16
IN HUSTON, J S; LAURENT, O; MARASCO, W A; SCHERMAN, D; WILS, P; ZHU, Q; QUAN, Z
PA (HUST-I) HUSTON J S; (LAUR-I) LAURENT O; (MARA-I) MARASCO W A; (SCHE-I) SCHERMAN D; (WILS-I) WILS P; (ZHUQ-I) ZHU Q; (QUAN-I) QUAN Z
CYC 96
PI WO 2002000914 A2 20020103 (200231)* EN 96p
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
AU 2001070142 A 20020108 (200235)
US 2002132990 A1 20020919 (200264)
ADT WO 2002000914 A2 WO 2001-US20182 20010625; AU 2001070142 A AU 2001-70142 20010625; US 2002132990 A1 Provisional US 2000-213653P 20000623, US 2001-888721 20010625
FDT AU 2001070142 A Based on WO 200200914
PRAI US 2000-213653P 20000623; US 2001-888721 20010625

L4 ANSWER 4 OF 46 USPATFULL

AN 2001:33025 USPATFULL
TI Composition of immunotoxins and retinoids and use thereof
IN Wu, YouNeng, Bethesda, MD, United States
Youle, Richard J., Garrett Park, MD, United States
PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. corporation)
PI US 6197528 B1 20010306
AI US 1999-249423 19990212 (9)
RLI Division of Ser. No. US 1994-238997, filed on 6 May 1994, now patented, Pat. No. US 5942230
DT Utility
FS Granted
EXNAM Primary Examiner: Huff, Sheela
LREP Morgan & Finnegan, L.L.P.
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 26 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 1271
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 46 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE 2
AN 2001:185685 BIOSIS
DN PREV200100185685
TI Human KDEL receptor.
AU Bandman, Olg; Hillman, Jennifer L.; Goli, Surya K.
ASSIGNEE: Incyte Pharmaceuticals, Inc.
PI US 6103874 August 15, 2000.
SO Official Gazette of the United States Patent and Trademark Office Patents, (Aug. 15, 2000) Vol. 1237, No. 3, pp. No Pagination. e-file.
ISSN: 0098-1133.
DT Patent
LA English

L4 ANSWER 6 OF 46 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 3
AN 2000:98760 CAPLUS
DN 132:133894
TI Inhibition of KDEL receptor-mediated return of heat shock protein complexes to the endoplasmic reticulum and their adjuvant use
IN Rothman, James E.; Mayhew, Mark; Hoe, Mee H.
PA Sloan-Kettering Institute for Cancer Research, USA
SO PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000006729	A1	20000210	WO 1999-US17147	19990728
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6160088	A	20001212	US 1998-124671	19980729
CA 2337692	AA	20000210	CA 1999-2337692	19990728
AU 9953245	A1	20000221	AU 1999-53245	19990728
EP 1100906	A1	20010523	EP 1999-938851	19990728

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
PRAI US 1998-124671 A 19980729
WO 1999-US17147 W 19990728
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 46 BIOTECHABS COPYRIGHT 2003 THOMSON DERWENT AND ISI
AN 2000-06139 BIOTECHABS
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion or proteins which are normally retained within the cell; herpes simplex virus-based vector e.g. plasmid pHSV1, retro virus vector and Moloney retro virus vector-mediated expression in transgenic animal for infectious disease and cancer therapy
AU Rothman J E; Mayhew M; Hoe M H
PA Sloan-Kettering-Inst.Cancer-Res.
LO New York, NY, USA.
PI WO 2000006729 10 Feb 2000
AI WO 1999-US17147 28 Jul 1999
PRAI US 1998-124671 29 Jul 1998
DT Patent
LA English
OS WPI: 2000-195296 [17]

L4 ANSWER 8 OF 46 USPATFULL
AN 2000:168135 USPATFULL
TI **KDEL receptor inhibitors**
IN Rothman, James E., New York, NY, United States
Mayhew, Mark, Tarrytown, NY, United States
Hoe, Mee H., Irvington, NY, United States
PA Sloan-Kettering Institute For Cancer, New York, NY, United States (U.S. corporation)
PI US 6160088 20001212
AI US 1998-124671 19980729 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: Achutamurthy, Ponnathapu; Assistant Examiner: Tung, Peter P.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 10 Drawing Figure(s); 30 Drawing Page(s)
LN.CNT 1537
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 9 OF 46 USPATFULL
AN 1999:99378 USPATFULL
TI Composition of immunotoxins and retinoids and use thereof
IN Wu, YouNeng, Bethesda, MD, United States
Youle, Richard J., Garrett Park, MD, United States
PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PI US 5942230 19990824
AI US 1994-238997 19940506 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Huff, Sheela; Assistant Examiner: Eyler, Yvonne
LREP Morgan & Finnegan, L.L.P.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 23 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 1312

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Not Inhb.

L4 ANSWER 10 OF 46 CAPLUS COPYRIGHT 2003 ACS
AN 1998:359390 CAPLUS
DN 129:147072
TI Hsp47 **binds** to the **KDEL receptor** and cell surface expression is modulated by cytoplasmic and endosomal pH
AU Sauk, John J.; Norris, Kathleen; Hebert, Carla; Ordonez, Jose; Reynolds, Mark
CS Department of Pathology, Dental School and UMAB Greenbaum Cancer Center, University of Maryland at Baltimore, Baltimore, MD, 21201, USA
SO Connective Tissue Research (1998), 37(1-2), 105-119
CODEN: CVTRBC; ISSN: 0300-8207
PB Gordon & Breach Science Publishers
DT Journal
LA English
RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 46 CAPLUS COPYRIGHT 2003 ACS
AN 1996:428695 CAPLUS
DN 125:79781
TI Purification and Characterization of the Human KDEL Receptor
AU Scheel, Andreas A.; Pelham, Hugh R. B.
CS MRC Laboratory of Molecular Biology, Cambridge, CB2 2QH, UK
SO Biochemistry (1996), 35(31), 10203-10209
CODEN: BICHAW; ISSN: 0006-2960
PB American Chemical Society
DT Journal
LA English

L4 ANSWER 12 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAY44970 Protein DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent
LA English
OS 2000-195296 [17]
DESC RGD-4C targeting sequence for **KDEL receptor inhibitor** protein.

L4 ANSWER 13 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAY44969 Protein DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent
LA English
OS 2000-195296 [17]
DESC Peptide-2 binding to erd 2 receptor.

L4 ANSWER 14 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAY44968 Protein DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent
LA English
OS 2000-195296 [17]
DESC Peptide-1 binding to erd 2 receptor.

L4 ANSWER 15 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAY44967 Protein DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent
LA English
OS 2000-195296 [17]
CR N-PSDB: AAZ50501
DESC **KDEL receptor inhibitor** protein-10.

L4 ANSWER 16 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAY44966 Protein DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent
LA English
OS 2000-195296 [17]
CR N-PSDB: AAZ50500
DESC **KDEL receptor inhibitor** protein-9.

L4 ANSWER 17 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAY44965 Protein DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent
LA English
OS 2000-195296 [17]
CR N-PSDB: AAZ50499
DESC **KDEL receptor inhibitor** protein-8.

L4 ANSWER 18 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAY44964 Protein DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent
LA English
OS 2000-195296 [17]
CR N-PSDB: AAZ50498
DESC **KDEL receptor inhibitor** protein-7.

L4 ANSWER 19 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAY44963 Protein DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent
LA English
OS 2000-195296 [17]
CR N-PSDB: AAZ50497
DESC **KDEL receptor inhibitor** protein-6.

L4 ANSWER 20 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAY44962 Protein DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent
LA English
OS 2000-195296 [17]
CR N-PSDB: AAZ50496
DESC **KDEL receptor inhibitor** protein-5.

L4 ANSWER 21 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAY44961 Protein DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent
LA English
OS 2000-195296 [17]

CR N-PSDB: AAZ50495
DESC **KDEL receptor inhibitor** protein-4.

L4 ANSWER 22 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAY44960 Protein DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent
LA English
OS 2000-195296 [17]
CR N-PSDB: AAZ50494
DESC **KDEL receptor inhibitor** protein-3.

L4 ANSWER 23 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAY44959 Protein DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent
LA English
OS 2000-195296 [17]
CR N-PSDB: AAZ50493
DESC **KDEL receptor inhibitor** protein-2.

L4 ANSWER 24 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAY44958 Protein DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent
LA English
OS 2000-195296 [17]
CR N-PSDB: AAZ50492
DESC **KDEL receptor inhibitor** protein-1.

L4 ANSWER 25 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAY44957 peptide DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent

LA English
OS 2000-195296 [17]
DESC Human papilloma virus antigenic peptide-5.

L4 ANSWER 26 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAY44956 peptide DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent
LA English
OS 2000-195296 [17]
DESC Human papilloma virus antigenic peptide-4.

L4 ANSWER 27 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAY44955 peptide DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent
LA English
OS 2000-195296 [17]
DESC Human papilloma virus antigenic peptide-3.

L4 ANSWER 28 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAY44954 peptide DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent
LA English
OS 2000-195296 [17]
DESC Human papilloma virus antigenic peptide-2.

L4 ANSWER 29 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAY44953 peptide DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent
LA English
OS 2000-195296 [17]

DESC Human papilloma virus antigenic peptide-1.

L4 ANSWER 30 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAY44952 peptide DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent
LA English
OS 2000-195296 [17]
DESC Human phospholamban oligomerisation domain.

L4 ANSWER 31 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAY44951 peptide DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent
LA English
OS 2000-195296 [17]
DESC Xenopus thrombospondin 4 trimerisation domain.

L4 ANSWER 32 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAY44950 peptide DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent
LA English
OS 2000-195296 [17]
DESC Human thrombospondin 4 trimerisation domain.

L4 ANSWER 33 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAY44949 peptide DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent
LA English
OS 2000-195296 [17]
DESC Human thrombospondin 3 trimerisation domain.

L4 ANSWER 34 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAY44948 peptide DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent
LA English
OS 2000-195296 [17]
DESC Mouse thrombospondin 3 trimerisation domain.

L4 ANSWER 35 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAY44947 peptide DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent
LA English
OS 2000-195296 [17]
DESC Human cartilage oligomeric matrix protein pentamerisation domain.

L4 ANSWER 36 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAY44946 peptide DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent
LA English
OS 2000-195296 [17]
DESC Rat cartilage oligomeric matrix pentamerisation domain.

L4 ANSWER 37 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAZ50501 DNA DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent
LA English
OS 2000-195296 [17]
CR P-PSDB: AAY44967
DESC **KDEL receptor inhibitor**-10 **DNA**.

L4 ANSWER 38 OF 46 DGENE (C) 2003 THOMSON DERWENT

AN AAZ50500 DNA DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent
LA English
OS 2000-195296 [17]
CR P-PSDB: AAY44966
DESC **KDEL receptor inhibitor**-9 **DNA**.

L4 ANSWER 39 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAZ50499 DNA DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent
LA English
OS 2000-195296 [17]
CR P-PSDB: AAY44965
DESC **KDEL receptor inhibitor**-8 **DNA**.

L4 ANSWER 40 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAZ50498 DNA DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent
LA English
OS 2000-195296 [17]
CR P-PSDB: AAY44964
DESC **KDEL receptor inhibitor**-7 **DNA**.

L4 ANSWER 41 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAZ50497 DNA DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent
LA English
OS 2000-195296 [17]
CR P-PSDB: AAY44963
DESC **KDEL receptor inhibitor**-6 **DNA**.

L4 ANSWER 42 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAZ50496 DNA DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent
LA English
OS 2000-195296 [17]
CR P-PSDB: AAY44962
DESC **KDEL receptor inhibitor**-5 **DNA**.

L4 ANSWER 43 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAZ50495 DNA DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent
LA English
OS 2000-195296 [17]
CR P-PSDB: AAY44961
DESC **KDEL receptor inhibitor**-4 **DNA**.

L4 ANSWER 44 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAZ50494 DNA DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent
LA English
OS 2000-195296 [17]
CR P-PSDB: AAY44960
DESC **KDEL receptor inhibitor**-3 **DNA**.

L4 ANSWER 45 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAZ50493 DNA DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent
LA English
OS 2000-195296 [17]

CR P-PSDB: AAY44959
DESC **KDEL receptor inhibitor**-2 **DNA**.

L4 ANSWER 46 OF 46 DGENE (C) 2003 THOMSON DERWENT
AN AAZ50492 DNA DGENE
TI **Inhibitors** of the **KDEL receptor** which comprises an oligomerization domain useful for promoting secretion of proteins which are normally retained within the cell -
IN Rothman J E; Mayhew M; Hoe M H
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI WO 2000006729 A1 20000210 87p
AI WO 1999-US17147 19990728
PRAI US 1998-124671 19980729
DT Patent
LA English
OS 2000-195296 [17]
CR P-PSDB: AAY44958
DESC **KDEL receptor inhibitor**-1 **DNA**.

=>
<------User Break------>

=>

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653sxs

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Jun 03	New e-mail delivery for search results now available
NEWS 4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 7	Sep 03	JAPIO has been reloaded and enhanced
NEWS 8	Sep 16	Experimental properties added to the REGISTRY file
NEWS 9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 11	Oct 24	BEILSTEIN adds new search fields
NEWS 12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 13	Nov 18	DKILIT has been renamed APOLLIT
NEWS 14	Nov 25	More calculated properties added to REGISTRY
NEWS 15	Dec 04	CSA files on STN
NEWS 16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 17	Dec 17	TOXCENTER enhanced with additional content
NEWS 18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 20	Feb 13	CANCERLIT is no longer being updated
NEWS 21	Feb 24	METADEX enhancements
NEWS 22	Feb 24	PCTGEN now available on STN
NEWS 23	Feb 24	TEMA now available on STN
NEWS 24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 25	Feb 26	PCTFULL now contains images
NEWS 26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 27	Mar 20	EVENTLINE will be removed from STN
NEWS 28	Mar 24	PATDPAFULL now available on STN
NEWS 29	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 30	Apr 11	Display formats in DGENE enhanced
NEWS 31	Apr 14	MEDLINE Reload
NEWS 32	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 33	Apr 21	Indexing from 1947 to 1956 being added to records in CA/CAPLUS
NEWS 34	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 35	Apr 28	RDISCLOSURE now available on STN
NEWS 36	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 37	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS 38	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated

NEWS EXPRESS	April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS	STN Operating Hours Plus Help Desk Availability

```
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:21:15 ON 15 MAY 2003

=> File bioscience health medicine meetings pharmacology research toxicology
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'ADISCTI' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 16:21:40 ON 15 MAY 2003

FILE 'ANABSTR' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (c) 2003 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'AQUASCI' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT 2003 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOCOMMERCE' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All
rights reserved

FILE 'BIOSIS' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHABS' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHDS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHNO' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 16:21:40 ON 15 MAY 2003
```

FILE 'CAPLUS' ENTERED AT 16:21:40 ON 15 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (c) 2003 DECHEMA eV

FILE 'CEN' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 16:21:40 ON 15 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DDFB' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DDFU' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DGENE' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGB' ACCESS NOT AUTHORIZED

FILE 'DRUGLAUNCH' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGMONOG2' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGNL' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGU' ACCESS NOT AUTHORIZED

FILE 'DRUGUPDATES' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'EMBASE' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 16:21:40 ON 15 MAY 2003

FILE 'FOMAD' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 International Food Information Service

FILE 'GENBANK' ENTERED AT 16:21:40 ON 15 MAY 2003

FILE 'HEALSAFE' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 IFI CLAIMS(R) Patent Services (IFI)

FILE 'JICST-EPLUS' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 Japan Science and Technology Corporation (JST)

FILE 'KOSMET' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (c) 2003 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 16:21:40 ON 15 MAY 2003

FILE 'NIOSHTIC' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 16:21:40 ON 15 MAY 2003
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2003)

FILE 'NUTRACEUT' ENTERED AT 16:21:40 ON 15 MAY 2003
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 16:21:40 ON 15 MAY 2003
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2003 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 WIPO

FILE 'PHAR' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 16:21:40 ON 15 MAY 2003
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 16:21:40 ON 15 MAY 2003

COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 Gale Group. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT 2003 THOMSON ISI

FILE 'SYNTHLINE' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 Prous Science

FILE 'TOXCENTER' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 ACS

FILE 'USPATFULL' ENTERED AT 16:21:40 ON 15 MAY 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 16:21:40 ON 15 MAY 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'VETU' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPINDEX' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'CBNB' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (c) 2003 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CHEMLIST' ENTERED AT 16:21:40 ON 15 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'CSNB' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (c) 2003 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ENERGY' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (c) 2003 USDOE for the IEA-Energy Technology Data Exchange (ETDE)

FILE 'HSDB' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 NATIONAL LIBRARY OF MEDICINE

FILE 'INIS' ACCESS NOT AUTHORIZED

FILE 'IPA' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 American Society of Hospital Pharmacists (ASHP)

FILE 'MSDS-CCOHS' ENTERED AT 16:21:40 ON 15 MAY 2003
Copyright Notice: Permission to copy is not required for this file

FILE 'MSDS-OHS' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 MDL INFORMATION SYSTEMS (MDL)

FILE 'NAPRALERT' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 Board of Trustees of the University of Illinois,

University of Illinois at Chicago.

FILE 'NLDB' ENTERED AT 16:21:40 ON 15 MAY 2003

FILE 'POLLUAB' ENTERED AT 16:21:40 ON 15 MAY 2003

FILE 'RTECS' ENTERED AT 16:21:40 ON 15 MAY 2003

FILE '1MOBILITY' ENTERED AT 16:21:40 ON 15 MAY 2003

FILE 'COMPENDEX' ENTERED AT 16:21:40 ON 15 MAY 2003

FILE 'COMPUAB' ENTERED AT 16:21:40 ON 15 MAY 2003

FILE 'CONF' ENTERED AT 16:21:40 ON 15 MAY 2003

FILE 'ELCOM' ENTERED AT 16:21:40 ON 15 MAY 2003

FILE 'IMSDRUGCONF' ENTERED AT 16:21:40 ON 15 MAY 2003

FILE 'PAPERCHEM2' ENTERED AT 16:21:40 ON 15 MAY 2003

FILE 'SOLIDSTATE' ENTERED AT 16:21:40 ON 15 MAY 2003

FILE 'BABS' ENTERED AT 16:21:40 ON 15 MAY 2003

FILE 'DIOGENES' ENTERED AT 16:21:40 ON 15 MAY 2003

FILE 'INVESTEXT' ENTERED AT 16:21:40 ON 15 MAY 2003

FILE 'USAN' ENTERED AT 16:21:40 ON 15 MAY 2003

FILE 'DKF' ENTERED AT 16:21:40 ON 15 MAY 2003

FILE 'FORIS' ENTERED AT 16:21:40 ON 15 MAY 2003

FILE 'FORKAT' ENTERED AT 16:21:40 ON 15 MAY 2003

```
FILE 'RUSSCI' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 Andrigal Ltd.

FILE 'SOLIS' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 Informationszentrum Sozialwissenschaften, Bonn (IZS)

FILE 'UFORDAT' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 Umweltbundesamt, D-14191 Berlin (UBA)

FILE 'AQUIRE' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 US Environmental Protection Agency (EPA)

FILE 'ULIDAT' ENTERED AT 16:21:40 ON 15 MAY 2003
COPYRIGHT (C) 2003 Umweltbundesamt, D-14191 Berlin (UBA)

=> s (thrombospondin 3) or thrombospondin3 or tsp3
  29 FILES SEARCHED...
  52 FILES SEARCHED...
  62 FILES SEARCHED...
L1          479 (THROMBOSPONDIN 3) OR THROMBOSPONDIN3 OR TSP3

=> s (pentamerization domain) (3A) (fusion protein)
  13 FILES SEARCHED...
  23 FILES SEARCHED...
  38 FILES SEARCHED...
  54 FILES SEARCHED...
  66 FILES SEARCHED...
L2            7 (PENTAMERIZATION DOMAIN) (3A) (FUSION PROTEIN)

=> s (oligomerization domain) (3A) (fusion protein)
  13 FILES SEARCHED...
  27 FILES SEARCHED...
  40 FILES SEARCHED...
  55 FILES SEARCHED...
  68 FILES SEARCHED...
L3           26 (OLIGOMERIZATION DOMAIN) (3A) (FUSION PROTEIN)

=> s l2 or l3
  52 FILES SEARCHED...
L4           33 L2 OR L3

=> s l1 and l4
  54 FILES SEARCHED...
  67 FILES SEARCHED...
L5            0 L1 AND L4
```

```
FULL ESTIMATED COST                                    179.73     179.94

=> s l1 and (pentamerization or pentamer or oligomer or oligomerization)
  29 FILES SEARCHED...
  60 FILES SEARCHED...
L6          72 L1 AND (PENTAMERIZATION OR PENTAMER OR OLIGOMER OR OLIGOMERIZAT
               ION)

=> s l1 (5A) (pentamerization or pentamer or oligomer or oligomerization)
  30 FILES SEARCHED...
  63 FILES SEARCHED...
L7          21 L1 (5A) (PENTAMERIZATION OR PENTAMER OR OLIGOMER OR OLIGOMERIZA
               TION)

=> duplicate
ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove
ENTER L# LIST OR (END):l7
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGLAUNCH, DRUGMONOG2, DRUGUPDATES, FEDRIP, FOREGE, GENBANK, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, SYNTHLINE, CHEMLIST, HSDB,
MSDS-CCOHS, MSDS-OHS, RTECS, CONF, IMSDRUGCONF, DIOGENES, INVESTEXT, USAN,
FORIS, FORKAT, UFORDAT, AQUIRE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
DUPLICATE PREFERENCE IS 'BIOSIS, BIOTECHNO, CANCERLIT, CAPLUS, DGENE, EMBASE,
ESBIOBASE, MEDLINE, SCISEARCH, TOXCENTER, USPATFULL'
KEEP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
PROCESSING COMPLETED FOR L7
L8             8 DUPLICATE REMOVE L7 (13 DUPLICATES REMOVED)

=> d l8 1-8 bib ab

L8   ANSWER 1 OF 8  USPATFULL
AN     2000:168135  USPATFULL
TI     KDEL receptor inhibitors
IN     Rothman, James E., New York, NY, United States
       Mayhew, Mark, Tarrytown, NY, United States
       Hoe, Mee H., Irvington, NY, United States
PA     Sloan-Kettering Institute For Cancer, New York, NY, United States (U.S.
       corporation)
PI     US 6160088              20001212
AI     US 1998-124671          19980729 (9)
DT     Utility
FS     Granted
EXNAM  Primary Examiner: Achutamurthy, Ponnathapu; Assistant Examiner: Tung,
       Peter P.
CLMN   Number of Claims: 13
ECL    Exemplary Claim: 1
DRWN   10 Drawing Figure(s); 30 Drawing Page(s)
LN.CNT 1537
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     The present invention relates to inhibitors of the KDEL receptor and
       therapeutic uses therefor. Certain proteins are functionally retained in
       the cellular endoplasmic reticulum via an interaction between a KDEL
       sequence and its receptor. According to the invention, blocking this
       interaction with a KDEL receptor inhibitor promotes the secretion of
       such proteins. In specific embodiments of the invention, KDEL receptor
       inhibitors may be used to promote the secretion of heat shock proteins,
       thereby rendering the secreted heat shock proteins more accessible to
       the immune system and improving the immune response to heat shock
       protein-associated antigens.

L8   ANSWER 2 OF 8  BIOSIS  COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE 1
AN   2000:190230  BIOSIS
DN   PREV200000190230
```

TI Expression and characterization of novel thrombospondin 1 type I repeat fusion proteins.
AU Qabar, Aziz N. (1); Bullock, Jeff; Matej, Louis; Polverini, Peter
CS (1) US ARMY CHPPM, 5158 Blackhawk Rd., Bldg. E-2100, Aberdeen Proving Ground, MD, 21010-5403 USA
SO Biochemical Journal, (Feb. 15, 2000) Vol. 346, No. 1, pp. 147-153. ISSN: 0264-6021.
DT Article
LA English
SL English
AB Thrombospondin (TSP)1 is a trimeric extracellular matrix protein that is held together by two cysteine residues. It is one of five TSP proteins that have been described to date with almost a universal heparin binding capability (TSP5 being the exception). The existence of two conformationally distinct structures in the TSP family (trimers and pentamers) prompted us to investigate the contribution of TSP1 trimeric structure to its inhibitory role in angiogenesis. We expressed full-length recombinant human TSP1, its type I repeats, and murine TSP3 in a human embryonic kidney cell line and evaluated their effect on human dermal microvascular endothelial cell (HMVEC) proliferation and sprouting into tube-like structures in vitro. Additionally, two chimaeric molecules were constructed so that the type I repeats of TSP1 were expressed as either dimers (TSP1-Ig chimaera) or **pentamers** (TSP1-**TSP3** chimaera). Dimeric and pentameric type I constructs are novel structures. We found that, similarly to full-length TSP1, intact trimeric type I repeats were inhibitory to HMVEC angiogenesis in vitro. However, dimeric and pentameric type I repeats of TSP1 only partially inhibited HMVEC proliferation and sprouting in vitro. TSP3, which is lacking type I repeats, had no inhibitory activity, confirming that type I repeats elicit the anti-angiogenic activity of TSP1.

L8 ANSWER 3 OF 8 SCISEARCH COPYRIGHT 2003 THOMSON ISI
AN 97:199820 SCISEARCH
GA The Genuine Article (R) Number: WL530
TI A chimeric murine **TSP3**/human TSP1 is a **pentamer** with abolished antiangiogenic activity.
AU Qabar A N (Reprint); Bullock J; Matej L
CS MADIGAN ARMY MED CTR, TACOMA, WA 98431
CYA USA
SO FASEB JOURNAL, (28 FEB 1997) Vol. 11, No. 3, pp. 365-365. Publisher: FEDERATION AMER SOC EXP BIOL, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998. ISSN: 0892-6638.
DT Conference; Journal
FS LIFE
LA English
REC Reference Count: 0

L8 ANSWER 4 OF 8 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AN 1997:184053 BIOSIS
DN PREV199799483256
TI A chimeric murine **TSP3**/human TSP1 is a **pentamer** with abolished antiangiogenic activity.
AU Qabar, Aziz N.; Bullock, Jeff; Matej, Louis
CS Madigan Army Med. Cent., Tacoma, WA 98431 USA
SO FASEB Journal, (1997) Vol. 11, No. 3, pp. A63. Meeting Info.: Annual Meeting of the Professional Research Scientists on Experimental Biology 97 New Orleans, Louisiana, USA April 6-9, 1997 ISSN: 0892-6638.
DT Conference; Abstract
LA English

L8 ANSWER 5 OF 8 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE 2
AN 1996:311523 BIOSIS